TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Schall Law Firm
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has filed a securities fraud class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) for allegedly making false and misleading statements about its drug candidate nimacimab, overstating its commercial and clinical prospects. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to join the lawsuit by January 16, 2026.

Insights
SKYE   negative

The company is accused of making false and misleading statements about its drug candidate's effectiveness and overstating commercial and clinical prospects, resulting in investor losses when the truth was revealed to the market.